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Peroxisome proliferator-activated receptor gamma (PPARγ) is a multifunctional transcription factor with important regulatory
roles in inﬂammation, cellular growth, diﬀerentiation, and apoptosis. PPARγ is expressed in a variety of immune cells as well as
in numerous leukemias and lymphomas. Here, we review recent studies that provide new insights into the mechanisms by which
PPARγ ligands inﬂuence hematological malignant cell growth, diﬀerentiation, and survival. Understanding the diverse properties
of PPARγ ligands is crucial for the development of new therapeutic approaches for hematological malignancies.
Copyright © 2008 Tatiana M. Garcia-Bates et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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1. INTRODUCTION
In order to understand the inﬂuence of PPARγ and its many
ligands on hematological malignancies and their normal cell
counterparts, we ﬁrst present background material to orient
the reader.
Peroxisome proliferator-activated receptors (PPARs) α,
β/δ,a n dγ are members of the nuclear hormone receptor
superfamily of transcription factors that regulate several
metabolic pathways in a tissue-selective manner [1]. All
PPARs form heterodimers with members of the retinoid
X receptor (RXR) subfamily of nuclear hormone recep-
tors and regulate initiation of transcription by binding to
the peroxisome proliferator response element (PPRE) in
p r o m o t e r so ft a r g e tg e n e s .D r u gc l a s s e ss u c ha sﬁ b r a t e s
and thiazolidinediones are used for lowering lipids and
improving insulin sensitivity, respectively, thus eﬀectively
reducing risk factors that lead to cardiovascular disease
[2, 3] and diabetes [4, 5]. PPARγ agonists have both
PPARγ-dependent and -independent eﬀects on coagulation,
thrombosis, angiogenesis, and tumor growth and metastasis
[6, 7]. PPARγ agonists also exert anti-inﬂammatory and
antiﬁbrotic eﬀects by negatively regulating the expression
of proinﬂammatory genes and by inhibiting myoﬁbroblast
diﬀerentiation [8–10]. Moreover, PPARγ agonists modulate
the activity of several transcription factors (e.g., NF-κB, AP-
1, and Stat3) [10–13] that regulate inﬂammation.
1.1. StructureofthehumanPPARγ gene
The human PPARγ is located on chromosome 3, band 3p25
[14]. This gene gives rise to the two well-known isoforms
of PPARγ,P P A R γ1, and PPARγ2, which function as tran-
scriptional activators or repressors in a context-dependent2 PPAR Research
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Figure 1: Schematic structure of the human PPARγ gene. The human PPARγ gene is located on chromosome 3, band 3p25, and is composed
of at least 11 exons that give rise to 9 transcript variants. Expression of PPARγ involves diﬀerential promoter usage in combination with
alternative splicing and polyadenylation site selection. The relative positions of the four known PPARγ promoters are designated as Pγ1-Pγ4.
The noncoding exons A1, A , and A2 are depicted by boxes in diﬀerent shades of gray or in black and white checked. These exons contribute
to the 5  UTR of transcripts γ1-γ1d, γ3a n dγ1tr. The transcript variants 1γ-1γd, γ3, and γ4 encode the PPARγ1 isoform. Exon B (diagonal
blue and white hatched box) encodes the 28 additional amino acids found at the amino terminus of human PPARγ2; the mouse PPARγ2
exon B encodes 30 amino acids. Exons 1–6 (light blue boxes) are common in all PPARγ1 transcripts and when they are spliced to exon B
encode full-length PPARγ2. Two additional exon regions have been recently identiﬁed, exon 3  (horizontal light blue and white hatched box)
and exon 4  (small light blue box). Inclusion of either of these coding regions in the processed mRNA transcript results in truncated PPARγ1
proteins lacking theligand bindingdomain (γ1tr andORF4, resp.).The sizes of the exon boxes approximate the relative lengths of each exon;
however, the introns (depicted as straight lines) are not drawn to scale. The positions of the stop codons are depicted by the hexagonal red
stop signs.
manner [15, 16]. Recent evidence suggests that the human
PPARγ gene is composed of at least 11 exons that give
rise to 9 transcript variants due to the combination of
diﬀerential promoter usage, alternative RNA splicing, and
polyadenylation site selection of the primary transcript
(Figure 1). To date, four promoters and three new exons A ,
3 ,a n d4   have been identiﬁed [14, 17–23]. Similar to exons
A1 and A2, exon A  is noncoding and contributes to the
5  UTR of several transcript variants (Figure 1). Inclusion
of exon 3  in the processed transcript produces a truncated
PPARγ1p r o t e i n( γ1tr) [22], as does the read-through of
exon 4 to include intron 4 sequences (γORF4) [23]. Both
truncated forms of PPARγ1( γ1tr and γORF4) lack the
coding regions for the ligand binding domain and function
in a dominant negative manner to wild type PPARγ1. The
truncated form of PPARγ (γ1tr) was discovered and cloned
from chronic myeloid leukemia K562 cells and enhanced cell
proliferation [22]. Similarly, γORF4 protein was found to
reside mainly in the nucleus and enhanced cell growth [23].
The complexity in processing the PPARγ primary transcript
likely leads to speciﬁc regulation of PPARγ functions in
a context-dependent manner. This may explain, at least
in part, the pleiotropic functions ascribed to PPARγ1a n d
PPARγ2[ 23–29].
1.2. Posttranslationalmodiﬁcationsregulate
PPARγ activity
Several reversible posttranslational modiﬁcations occur that
regulate the transactivation potential of PPARγ (Figure 2).
The phosphorylation status and activity of the PPARs are
regulated in both ligand-dependent and ligand-independent
manners, the details of which have been recently reviewed
[30]. Whereas serine phosphorylation of PPARα increases
its transcriptional activity in hepatocytes, MAPK/ERK-
mediated phosphorylation of Ser84/112 on PPARγ1/2 leads
to attenuation of PPARγ transcriptional activity and its
possible relocalization from the nucleus to the cytoplasm
[30–33]. Furthermore, both Ser84/112 phosphorylation [34]
and ligand binding [35] contribute to the targeting of
PPARγ to ubiquitin-proteasome degradation. In contrast,
ERK5 activates PPARγ1 in a phosphorylation-independent
manner by directly interacting with the hinge-helix 1 region
[36].Tatiana M. Garcia-Bates et al. 3
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Figure 2: Reversible posttranslational modiﬁcations of PPARγ. The superfamily of nuclear hormone receptors possesses conserved structural
and functional domains including PPARγ. The A/B domain is the hypervariable region containing the putative activation function-1 (AF-
1) domain. Human PPARγ2 contains a 28 amino acid amino terminal region that arises from diﬀerential promoter use and splicing
(see Figure 1). The primary structure of the C-domain is the most conserved and contains the DNA binding domain (DBD). The D-
domain (Hinge) allows for conformational change following ligand binding to promote coregulator (coactivator or corepressor) docking;
binding of ERK5 to the hinge helix 1 region potentiates ligand-dependent PPARγ1 activity. The E/F region contains the ligand binding
domain (LBD) of PPARγ and the activation function-2 (AF-2) domain that participates in ligand-dependent degradation mediated by the
ubiquitin-proteasome pathway. PPARγ heterodimerizes with its binding partners, RXR family members, through the E/F domain as well.
Reversible posttranslational modiﬁcations of PPARγ regulate its activation. In addition to proteasome-mediated degradation, PPARγ can be
phosphorylated by MAP kinases at S84/112 (position of serine in PPARγ1/PPARγ2) or SUMO-1 modiﬁcation. Two SUMOylation consensus
motifs have been described. Whereas SUMOylation at a conserved ψKXEXXSP (where ψ is a hydrophobic amino acid and X can be any
residue) is linked to serine phosphorylation events, SUMOylation at ψKXE/D motifs are not generally linked to MAPK phosphorylation.
The lysine residues of the three SUMOylation motifs identiﬁed on PPARγ1/2 are depicted in red. The serine residue phosphorylated by
MAPKs is depicted in yellow. Both serine phosphorylation and SUMOylation negatively regulate PPARγ activity.
In a recent review, Straus and Glass [10] discuss various
mechanisms for nuclear hormone receptor-dependent tran-
srepression of target genes by the PPARs, Liver X Receptors
(LXRs), and glucocorticoid receptor (GR). Posttranslational
modiﬁcation with small ubiquitin-like modiﬁer (SUMO)-
1 converts these nuclear hormones from transactivators to
transrepressors of gene expression [10, 37]. SUMOylated
PPARγ1 binds to the corepressor complex interfering with
its clearance, thereby preventing transactivation of NF-κB
target genes [10, 37]. To date, modiﬁcations of PPARγ with
SUMO-1 occur on three lysine residues (K79/107,K 319/347,
and K367/395)o fP P A R γ1/2 [38–40]. Moreover, PPARγ’s
dimerization partner, RXRα, is also SUMOylated [41]. A
summaryofPPARγ posttranslationalmodiﬁcationsisshown
inFigure 2.SUMOcompeteswithubiquitinformodiﬁcation
of lysines on some proteins, thereby rescuing the protein
from ubiquitin-proteasome mediated proteolysis [42]. In
addition to increasing protein half-life, SUMOylation plays a
role in nuclear-cytoplasmic traﬃcking, cell-cycle regulation,
genome integrity, transcription, and cancer progression and
metastasis [43–47].
2. PPARγ LIGANDS
Transcriptional activity of PPARγ is controlled primar-
ily by ligand binding [48]. PPARγ has a large ligand
binding pocket, which enables it to bind a variety of
ligands [49]. PPARγ ligands include both synthetic and
natural molecules [48]. Many of the naturally occurring
ligands are fatty acids or fatty acid derivatives obtained
through the diet or from intracellular signaling pathways.
These include lysophosphatidic acid [50], nitrolinoleic acid
[51], 9- and 13-hydroxyoctadecadienoic acids (9- and
13-HODE) [48, 52], 15-hydroxyeicosatetraenoic acid (15-
HETE)[25],prostaglandinD2 (PGD2),and15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2)[ 25, 48, 49, 53–55]. 15d-PGJ2
is thought to be the most potent endogenous ligand for
PPARγ, activating it at low micromolar concentrations [25,
52, 53]. PGD2 and 15d-PGJ2 are derived from arachidonic
acid by the catalytic activities of the cyclooxygenase-2
(Cox-2) and prostaglandin D synthase [53, 54, 56]. PGD2
spontaneously undergoes a series of dehydration reactions to
form the PGJ family of prostaglandins, including 15d-PGJ2,4 PPAR Research
and 15d-PGD2, which can also transactivate PPARγ [56–
60].
Synthetic PPARγ ligands, including drugs of the thi-
azolidinedione (TZD) family (e.g., ciglitazone, pioglita-
zone, rosiglitazone, and troglitazone), have potent insulin-
sensitizing properties [3, 25, 49, 56, 61, 62]. Because of this,
somearecommonlyusedforthetreatmentoftype2diabetes
[48, 61]. There also exist TZDs, such as TZD18, that act as
dual PPARα/PPARγ agonists [63].
There are also many non-TZD synthetic compounds
that can function as PPARγ agonists. Some of these are:
L-tyrosine-based GW-7845 and GW-1929 [48, 52], diin-
dolymethane analogs [48, 64], certain nonsteroidal anti-
inﬂammatory drugs (NSAIDs) (i.e., indomethacin, ibupro-
fen, ﬂufenamic acid, and fenoprofen [25, 27, 65]), and the
novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-
dien-28-oicacid(CDDO)anditsderivatives[48,66].CDDO
bindstoPPARγ withnanomolaraﬃnity[48,66]anddisplays
antiproliferative and diﬀerentiating activities, making it
useful as a chemotherapeutic agent. Derivatives of CDDO
have more useful pharmacodynamic and pharmacokinetic
properties than CDDO itself [67, 68]. Importantly, some
CDDO derivatives are orally active and are remarkably well-
tolerated in humans [69].
PPARγ ligands, including CDDO, can reduce cell pro-
liferation, migration, cytokine production, expression of
costimulatory, and adhesion molecules and can promote
apoptosis [48]. These ﬁndings suggest that PPARγ lig-
ands may be eﬃcacious in the treatment of hematological
malignancies [48]. However, numerous side eﬀects have
been observed in patients treated with TZDs [49]. For
example, troglitazone has caused hepatotoxicity [49]. TZDs
alsoinduceweightgain,edema[70],increasedlipoprotein(a)
concentrations [3, 49], and probably enhance risk of heart
failure and cardiac hypertrophy [48, 71, 72]. Therefore, it
is highly desirable to develop PPARγ ligands with improved
therapeutic proﬁles [48].
The identiﬁcation of “selective PPARγ modulators”
(SPPARγMs) has become the object of intense recent
interest, with the idea that one might modulate the genes
necessarytoachievetherapeuticpotential,whilenotaﬀecting
the genes involved in producing side eﬀects [49]. This
conceptisplausiblebecauseSPPARγMstakeadvantageofthe
large PPARγ ligand binding pocket, which allows a variety
of ligands to bind in diﬀerent orientations [15, 61, 73–
76].SPPARγMstheninducespeciﬁcconformationalchanges
of the receptor which create diﬀerent interaction surfaces,
favoring the recruitment of only a subset of coregulators
[48, 49, 77, 78]. This subset of coregulators will allow the
inductionofsome,butnotalltargetgenes[15,49,61,74,79–
83]. The SPPARγM concept has been shown to hold true
for some currently recognized PPARγ ligands. For example,
CDDO is a more potent inducer of apoptosis than are
TZDs [48]. This may be because the PPARγ target genes
activated by CDDO are diﬀerent from those activated by
TZDs [48]. CDDO is less eﬀective than rosiglitazone in
recruiting coactivators, but it can eﬀectively promote the
release of corepressors from PPARγ target genes [48]. A
greater understanding of the activities of the various PPARγ
ligands will depend on the identiﬁcation of the speciﬁc
coregulators recruited to PPARγ target genes in response to
binding to speciﬁc ligands [25].
3. PPARγ AND THE IMMUNE SYSTEM
One of the earliest indications of an important role for
PPARγ in the immune system was the discovery of its
expression in mouse spleen [84]. After this ﬁnding, our
laboratory and others began searching for PPARγ expression
and function in immune cells. To date, PPARγ expression
has been found in monocytes/macrophages, dendritic cells,
granulocytes (i.e., neutrophils, eosinophils, and basophils),
mast cells, T cells, and B cells, and most recently our
laboratory found PPARγ in human platelets [84–90].
PPARγ ligands have been shown to have anti-inﬂam-
matory eﬀects on cells of the innate and adaptive immune
system [91–94]. In macrophages, PPARγ has an important
role in regulating lipid metabolism, as well as in the gen-
eration of macrophage-derived foam cells in atherosclerotic
lesions [95–98]. Upon phorbol myristyl acetate (PMA) stim-
ulation, PPARγ ligands can inhibit macrophage activation
and production of inﬂammatory cytokines (e.g., TNFα,
IL-1β, and IL-6), inducible nitric oxide synthase (iNOS),
gelatinase B, and scavenger receptor A (SR-A) [89, 99,
100]. Moreover, PPARγ activation can skew macrophage
diﬀerentiation into a more anti-inﬂammatory phenotype
[101]. In dendritic cells, PPARγ activation can inhibit the
production of IL-12 and of chemokines involved in the
recruitment of Th1 lymphocytes, therefore, favoring a type
2i m m u n er e s p o n s e[ 90]. PPARγ ligands also enhanced the
development of a dendritic cell phenotype that: (1) has
increased endocytic activity and (2) induces the expansion
of invariant natural killer T (NKT) cells [102].
PPARγ also plays a role in T lymphocyte function, and its
levels are upregulated following their activation [103, 104].
PPARγ expression and activation can inhibit T lymphocyte
proliferation and reduce the production of IFNγ,T N F α,
and IL-2 [92, 105, 106]. These inhibitory eﬀects result from
the direct interaction between PPARγ and the transcription
factor nuclear factor of activated T cells (NFAT) [107]. Our
laboratory demonstrated that mouse and human T cells
express PPARγ, and treatment with PPARγ ligands induces
apoptosis in malignant T cells [103, 104]. Recent ﬁndings
reported by Wohlfert et al. could illuminate yet another
regulatory role for PPARγ in the immune system [108]. In
their study, PPARγ activation enhanced the generation of
CD4+ CD25+ regulatory T cells (Tregs). Tregs have been
demonstrated to play a key role in negatively regulating
autoimmunity and immune responses [109]. There are
two diﬀerent subtypes of Tregs: thymus-derived natural
Tregs (nTregs) and inducible Tregs (iTregs), which develop
from CD4+ CD25− eﬀector T cells in the periphery. [109–
111]. Wohlfert et al. showed that ciglitazone enhanced
the conversion of eﬀector T lymphocytes into inducible
Tregs (iTregs). Moreover, PPARγ expression in natural Tregs
(nTregs) was required for the in vivo eﬀects of ligand
treatment in a murine model of graft versus host disease
[108]. These ﬁndings suggest that PPARγ ligands enhanceTatiana M. Garcia-Bates et al. 5
the activity of Tregs while dampening the activation of other
T lymphocyte subsets. PPARγ was also shown to have a
physiological role in regulating B lymphocyte function. In
studies using PPARγ haploinsuﬃc i e n tm i c e ,Bl y m p h o c y t e s
exhibited increased proliferation and survival, enhanced
antigen speciﬁc immune responses and spontaneous NF-
κBa c t i v a t i o n[ 15, 112]. Our laboratory demonstrated that
both normal and malignant B lymphocytes express PPARγ,
and that exposure to certain PPARγ ligands inhibits B cell
proliferation and can induce apoptosis [85, 93, 113].
In summary, PPARγ activation has antiproliferative and
proapoptotic eﬀects and dampens cytokine production in
several immune cells. PPARγ ligands can also attenuate
several inﬂammatory diseases such as inﬂammatory bowel
disease [114–119], multiple sclerosis [120–122], rheumatoid
arthritis [112, 123], and psoriasis [124–126]. These ﬁndings
suggest that PPARγ ligands may be useful for the treatment
of immunological diseases, which include myelo and lym-
phoproliferative disorders.
4. PPARγ AND ITS CONTROVERSIAL ROLE AS
A TUMOR SUPPRESSOR GENE
As evidence accumulated to support that PPARγ ligands
are inhibitors of cell proliferation and inducers of cell
diﬀerentiation, attention turned to the role of PPARγ in the
onset and development of cancer. The potential of PPARγ
ligands as anticancer drug therapies has been explored in
cells from various malignant tissues, including those of
adipose, colon, breast, prostate, lung, pancreas, bladder, and
stomach origin [26, 127]. There is emerging evidence for a
direct role of PPARγ functional mutations in the initiation of
several common human cancers, such as colon, prostate, and
thyroid [28, 128–130]. For example, in a study of 55 patients
with sporadic colon cancers, four somatic PPARγ mutations
werefound.[129].Also,ahemizygousdeletionofPPARγ was
identiﬁed in 40% of prostate cancers [128]. Furthermore, a
fusion protein derived from the paired box gene 8 (PAX8)
and PPARγ genes (PPARγ-PAX-8) was detected in thyroid
cancers, which causes PPARγ not only to be functionally
inactive but also to function as a dominant negative form
of PPARγ [28, 131]. As described earlier, the PPARγ gene
is mapped to human chromosome 3, band 3p25 [14].
Interestingly, 3p deletions have been identiﬁed in several
hematological cancers, including acute myeloid leukemias
(AML), myelodysplastic syndromes (MDS), Philadelphia
chromosome-positive chronic myeloid leukemia (CML),
acute lymphoblastic leukemias (ALL), chronic lymphopro-
liferative disorder (CLD), and non-Hodgkin’s lymphomas
(NHL) [132]. These observations suggest that PPARγ plays
ar o l ea sat u m o rs u p p r e s s o rg e n ea n d ,a ss u c h ,m a yb ea
therapeutic target for cancer. Studies in liposarcoma [133]
and in xenograft models of prostate [134] and colon cancer
[135] support this hypothesis. However, a study using a
large number of human tumor samples and cell lines (n =
397), including those from leukemias, found no detectable
abnormalities, either in PPARγ exon 3 (DBD) or in exon 5
(LBD), suggesting that PPARγ gene mutations may occur,
but are rare [136].
The expression levels and/or the transactivation of
PPARγ may be impaired in certain cancers. In human lung
cancer, decreased expression of PPARγ correlated with poor
prognosis [29] and well-diﬀerentiated adenocarcinomas had
more PPARγ expression than poorly diﬀerentiated varieties
[137]. In addition, a study performed by Jansen et al.
demonstratedthattheabnormalPML-RARα(promyelocytic
leukemia-retinoic acid receptor alpha) fusion protein found
in acute promyelocitic leukemia (APL) interferes with PPAR
function [138]. Similarly, Hamadani et al. showed that
diﬀerent X-RARα fusion proteins found in APL can inhibit
the transactivation of PPARγ, and that this repression can be
released by the addition of PPARγ ligands [139, 140]. These
ﬁndings suggest that (1) PPARγ may be inactive in APL,
(2) this may contribute to the undiﬀerentiated phenotype,
and (3) PPARγ ligands may help sensitize APL cells to the
diﬀerentiating eﬀects of all-trans-retinoic acid (ATRA).
5. PPARγ AND PPARγ LIGANDS AS POTENTIAL
THERAPY FOR HEMATOLOGICAL MALIGNANCIES
5.1. Myeloidmalignancies
5.1.1. Acutemyeloidleukemia(AML)
Acute myelogenous leukemia (AML) constitutes about 25%
of all leukemias in adults in the Western World. It ranks as
the second most frequent type of leukemia in adults after
chronic lymphocytic leukemia, with more than 13000 new
cases, and nearly 9000 deaths from AML in the U.S. in 2007
[141]. Unfortunately, this type of leukemia has one of the
lowest survival rates, about 20% [142]. There are several
subtypes of AML, including acute promyelocytic leukemia
(APL). The most common cause of APL is a translocation
between chromosome 15 and 17, t(15;17), that leads to the
generation of the PML/RARα fusion gene. The resulting
fusion protein arrests the maturation of myeloid cells at the
promyelocytic stage and leads to the increased proliferation
of promyelocytes [143]. The cell lines typically used to study
APL are NB4 and HL-60. NB4 has the t(15;17) translocation,
while HL-60 does not [144]. In addition to chemotherapy
and stem cell transplantation, treatments for APL also
include diﬀerentiation therapy using all-trans-retinoic acid
(ATRA) which has led to long-term disease-free survival in
70–80% of cases of this AML subtype [145].
A ne a r l ys t u d yp e r f o r m e db yF u j i m u r ae ta l .d e m o n -
strated that treatment with troglitazone inhibited HL-60 cell
growth by a G1 cell cycle arrest and induced their diﬀerenti-
ation to monocytes [146]. A similar, G1 arrest was observed
in all other hematopoietic cell lines examined. Furthermore,
diﬀerentiation into the monocytic lineage was observed not
only in the myelogenous and promonocytic cell lines, but
also in an erythroleukemia cell line [146]. Data shown by
Yamakawa-Karakida et al. demonstrated that PPARγ activa-
tionbybothtroglitazoneand15d-PGJ2 inhibitsproliferation
and induces apoptosis in promyelocytic leukemia cells under
serum-free conditions [147]. The induction of apoptosis
was caspase-3 dependent, as treatment with a caspase-3
inhibitor completely abolished cell death. Although there6 PPAR Research
were no changes in antiapoptotic or proapoptotic proteins,
the expression levels of the proto-oncogene product c-
myc were drastically reduced after 24 hours of troglitazone
treatment while DNA binding by Tcf-4, a transcription
factor responsible for c-myc expression, was completely
inhibited [147]. Troglitazone and 15d-PGJ2 were found by
Liu et al. to signiﬁcantly induce apoptosis in K562 and HL-
60cellsbyupregulatingthelevelsoftheproapoptoticprotein
Bax and downregulating antiapoptotic proteins such as
survivin and Bcl-2 [148]. Furthermore, these PPARγ ligands
downregulated the expression of cyclooxygenase-2 (COX-2),
antiapoptotic proteins Bcl-2, Bcl-xL, and Mcl-1, upregulated
Bax and activated caspase 3 in human monocytic leukemia
cells [149]. Recent observations reported by Han et al.
revealed that 15d-PGJ2 was able to sensitize tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL)-
resistant leukemic HL-60 cells to TRAIL-induced apoptosis
[150]. This eﬀect of 15d-PGJ2 was PPARγ-independent, as
treatment with a PPARγ antagonist did not rescue the cells
from apoptosis. These results were consistent with studies
performed in other cancer cells where 15d-PGJ2 enhanced
TRAIL-induced apoptosis [151]. In a human eosinophilic
leukemia cell line, EoL-1, treatment with troglitazone caused
aG 0/G1 cell cycle arrest that correlated with increased
mRNA levels of the cyclin-dependent kinase (cdk) inhibitor,
p21WAF1/CIP1. Troglitazone exerted a similar induction of
p21 mRNA accompanied by inhibition of cell proliferation
inU937cellsandintheKPB-M15humanmyelomonoblastic
cell line [152]. These ﬁndings suggest that this PPARγ ligand
inhibits myeloid leukemia cell proliferation at least in part
by upregulating p21 [152]. Aside from its growth inhibitory
and apoptosis-inducing properties, 15d-PGJ2 has also been
shown to decrease the expression of metalloproteinases
in AML, therefore, inhibiting leukemic cell adhesion and
invasion of the extracellular matrix (ECM) [153].
A recent study investigated the antileukemia eﬀects and
the molecular mechanism of action of a novel PPARγ
ligand, DIM#34, in AML. DIM#34 can inhibit cell growth
and induce apoptosis through PPARγ-dependent and -
independent mechanisms. Cell death was associated with
defective extracellular signal-regulated kinase (ERK) activity,
and inhibition of Bcl-2 phosphorylation [154].
Konopleva et al. demonstrated growth inhibitory, dif-
ferentiative, and apoptotic eﬀects of PPARγ ligands in
cells from a variety of leukemias, including AML [155].
Addition of RXR or RAR ligands (i.e., LG100268 and
ATRA, resp.) in combination with PPARγ ligands enhanced
the diﬀerentiative and growth-suppressive eﬀects. Hirase
et al. reported similar ﬁndings that the antiproliferative,
proapoptotic, and/or diﬀerentiating eﬀects of TZDs on HL-
60 cells were further enhanced by the addition of the RXR-
selective ligand, LG100268 [156]. PPARγ ligands have also
been shown to inhibit the clonal proliferation of U937
myelomonocytic leukemia cells by a G1 cell cycle arrest, and
that treatment with both PPARγ ligand (troglitazone) and
LG100268 had synergistic inhibitory eﬀects on clonal growth
[157]. Finally, recent work by Yasugi et al. reported that
both pioglitazone and 15d-PGJ2 inhibited cell proliferation
in NB4 cells and that combined with ATRA, these PPARγ
ligands also induced myeloid diﬀerentiation and lipogenesis
[158].
The PPARγ-ligand CDDO and its C-28 methyl ester
derivative (CDDO-Me) have also shown prodiﬀerentiative
properties in myeloid leukemia cells [159–161]. CDDO-
Me induced granulo-monocytic diﬀerentiation in HL-60
cells and monocytic diﬀerentiation in primary AML cells.
Interestingly, while colony formation of AML progenitors
was signiﬁcantly inhibited, normal CD34+ progenitor cells
were less aﬀe c t e d .T h em o r ep o t e n te ﬀect of CDDO-Me
on leukemic cells compared to normal progenitor cells
suggests that CDDO-Me has potential as a new therapeutic
agent for the treatment of hematological malignancies [159].
Another group found that low doses of CDDO promoted
phagocytosis and granulocytic diﬀerentiation in HL-60 cells
and primary blasts from AML patients through the regula-
tion of CCAAT enhancer-binding protein (CEBPA) [162].
CEBPA is an important transcription factor for granulocytic
diﬀerentiation. CDDO upregulated the transcriptionally
active p42 CEBPA, while downregulating the inactive p30
CEBPA, thereby enhancing CEBPA-regulated genetranscrip-
tion.TheseﬁndingssuggestthepotentialuseofCDDOinthe
treatment of CEBPA-defective AML subtypes.
As proposed earlier, PPARγ transactivation may be
impairedinAML,andPPARγ ligandsmaybeabletosensitize
AML cells to the prodiﬀerentiation eﬀects of ATRA [138,
139]. In light of this, a recent study revealed that CDDO
enhanced ATRA-induced diﬀerentiation and apoptosis both
in the ATRA-sensitive APL cell line, NB4, and an ATRA-
resistant cell line, MR2 [163]. These eﬀects were partially
dependent on PPARγ, as inhibition of PPARγ either by a
speciﬁc inhibitor (T007) or by siRNA diminished CDDO-
induced APL diﬀerentiation [163].
CDDO induces apoptosis in human myeloid leukemia
cells by promoting loss of mitochondrial membrane poten-
tial, leading to cytochrome c release and activation of cas-
pases [155, 160, 162, 164]. However, Bcl-xL overexpression
only partially inhibited cytochrome c release and caspase
activation, indicating that CDDO can activate caspases 3
and 8 in a cytochrome c-independent manner [160]. Similar
ﬁndings were shown by Konopleva et al. where CDDO
activated both caspase-dependent and -independent cell
death [164]. CDDO also promotes tumor necrosis factor
(TNF)-induced apoptosis in human leukemia cells. CDDO
exposure did not inhibit NF-κB translocation into the
nucleus, but rather inhibited a step after translocation, such
as the NF-κB-dependent resynthesis of the inhibitor of NF-
κB, IκBα [165]. Similarly, Shishodia et al. demonstrated that
CDDO-Me inhibited both constitutive and inducible NF-κB
activity in human leukemic cells. In contrast to the previous
study [165], CDDO-Me-induced NF-κB inhibition occurred
through suppression of IκBα kinase activation, IκBα phos-
phorylation, IκBα degradation, p65 nuclear translocation,
and NF-κB-mediated reporter gene transcription [166].
These results lead to a downregulation of NF-κBt a r g e t
genes and enhanced apoptosis induced by TNF and other
chemotherapeutic agents.
Another CDDO derivative, C-28 imidazole (CDDO-
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the growth of human leukemia cells in vitro, as well as
murine melanoma and leukemia cells in vivo [167]. The
mechanismofCDDOandCDDO-Im-inducedapoptosishas
been attributed to a disruption of intracellular redox balance
by increasing reactive oxygen species (ROS) and decreasing
intracellular glutathione (GSH) concentrations [168].
Another subtype of AML is the acute myelomonocytic
leukemia (AMML). A well established cell line derived from
a child with AMML, THP-1, is often used to study this
disease [169]. Several studies have shown that macrophages
and myelomonocytic leukemias express PPARγ and that
PPARγ agonists can induce diﬀerentiation of THP-1 cells
into macrophages, as shown by the expression of CD36
scavenger receptors, as well as CD11b, CD14, and CD18
[97]. Another study showed that PPARγ1 expression levels
were upregulated by 9-cis retinoic acid (9-cis RA) in THP-
1 cells coincident with suppression of cell growth [170].
Moreover,additionofaspeciﬁcPPARγ ligandenhanced9-cis
RA-induced growth inhibition [170]. A reduction in THP-1
cell migration also occurred in response to PPARγ ligands
and was due to downregulation of metalloproteinase-9
expression [171]. These ﬁndings suggest that PPARγ ligands
may be beneﬁcial in preventing metastasis of monocytic
leukemia cells. Indeed, PPARγ ligands also have angiostatic
properties because of their inhibitory eﬀects on endothelial
diﬀerentiation and on vascular endothelial growth factor
(VEGF)-induced angiogenesis in vivo [172]. Recently, Ho
et al. reported that the pigment epithelium derived factor
(PEDF), a potent antiangiogenic factor, can induce THP-1
apoptosis and necrosis by inducing PPARγ protein expres-
sion. In their study, PEDF-induced apoptosis was shown
to be PPARγ-induction-dependent. Treatment with PPARγ
antagonist and PPARγ siRNA attenuated PEDF-induced
apoptosis. Transient expression of PPARγ using a PPARγ
expression plasmid reproduced the PEDF-eﬀects. Impor-
tantly, the PPARγ induced by PEDF was transcriptionally
active. These results suggest a PPARγ-dependent induction
of apoptosis in THP-1 cells [173].
5.1.2. Chronicmyeloidleukemia(CML)
Chronic myelogenous leukemia (CML) is a myeloprolif-
erative disorder that aﬀects all hematopoietic cell types.
I tc o n s t i t u t e s1 5t o2 0 %o fa d u l tl e u k e m i a s[ 174]. The
American Cancer Society anticipated diagnosis of about
4570 new cases of CML in 2007 [174]. CML is charac-
terized by a genetic abnormality known as Philadelphia
(Ph) chromosome, resulting from a translocation between
chromosomes 9 and 22, t(9;22)(q34;q11). This translocation
generates a fusion protein called BCR-ABL which is a consti-
tutively active tyrosine kinase responsible for uncontrolled
cell proliferation and enhanced cell survival [175]. Treat-
ments for this disease include splenic irradiation, stem cell
transplantation, and interferon alpha (IFNα) administration
with combination chemotherapy. A speciﬁc tyrosine kinase
inhibitor, Imatinib, was introduced in the late 1990s and is
a standard treatment for CML. However, clinical resistance
to imatinib has been described in CML patients, where BCR-
ABL gene mutations or ampliﬁcations have occurred [176,
177]. Therefore, development of new therapeutic strategies
to overcome imatinib resistance is needed. Dual PPARα and
γ ligands have been tested, either alone or in combination
with Imatinib, to overcome drug resistance. A characteristic
cell line used to study CML is K562, which was established
from a patient with CML in the acute phase [178]. Recently,
a study was performed using a synthetic dual PPARα/PPARγ
agonist,TZD18,inhumanCMLmyeloidblastcrisiscelllines
[63]. In this study, treatment with TZD18, both alone and in
combinationwithImatinib,inhibitedCMLproliferationand
induced apoptosis. These eﬀects were PPARα and PPARγ-
independent, as neither PPARα nor PPARγ antagonists were
able to rescue cell proliferation and survival. These results
were reported previously by the same group in Ph-positive
lymphocytic leukemia cell lines, where TZD18 promoted
cell death and acted synergistically to enhance the eﬀect of
Imatinib [179]. Hirase et al. tested the eﬀects of TZDs in
K562 cells, which have an erythroid nature and the potential
to diﬀerentiate into megakaryocytes [180]. TZD inhibited
both cell proliferation and the erythroid phenotype of K562
cells. These results were accompanied by a reduction in
erythroid lineage-transcription factor, GATA-1, levels [180].
Therefore, PPARγ ligands may serve a therapeutic use for
the treatment of other types of myeloproliferative disorders
where there is an overproduction of erythrocytes, such as
p o l y c y t h e m i av e r a( P V ) .
5.2. Lymphoidmalignancies
5.2.1. Acutelymphoblasticleukemia(ALL)and
non-Hodgkin’slymphomas
Acute lymphoblastic leukemia (ALL) is a malignant disorder
that arises from uncontrolled proliferation of lymphocytic
progenitors. The disease is most commonly diagnosed in
children, but can also occur in adults. About 80–90% of
ALL patients can achieve complete remission with currently
available therapy. Yet, many patients eventually relapse, and
only 35% of individuals have a long-term leukemia-free
survival (LFS) [181, 182]. Therefore, development of new
treatment approaches to improve both the cure rate and
the quality of life of patients with ALL is greatly needed.
ALL involving hyperproliferation of B lymphocyte progen-
itors (B-ALL) is frequently associated with a translocation
between the c-myc gene on chromosome 8q24 and any of
the three immunoglobulin genes located on chromosomes
14q32, 2p11, or 22q11. This translocation results in c-myc
overexpression and correlates with poor prognosis [183,
184]. The members of the Myc family, including c-myc,a r e
involved in regulation of proliferation and development of
normal and malignant cells [185].
An investigation by Zang et al. revealed that the PPARγ
ligands pioglitazone and 15d-PGJ2 suppressed cell growth
in G1 phase and induced apoptosis in a dose-dependent
manner in B-ALL cell lines. Apoptosis was found to be
partly caspase-dependent, as treatment with a pan-caspase
inhibitor partially reversed this eﬀect [186]. Similar ﬁndings
were shown in B-ALL with t(14;18), in which troglitazone
not only induced G1 phase growth arrest and apoptosis,8 PPAR Research
but also downregulated the expression of c-myc mRNA and
protein [187].
Our group has demonstrated that: (1) both normal
and malignant B lineage cells express PPARγ mRNA and
protein, and (2) exposure to certain small molecule PPARγ
ligands, including 15d-PGJ2, inhibits proliferation and
induces apoptosis in these cells [85, 113]. Subsequently, we
reported that PPARγ ligand-induced apoptosis was mainly
PPARγ-independent, since it was not prevented either by
aP P A R γ antagonist nor a dominant negative form of
PPARγ (PPARγ-DN) [94]. We reported that the apoptotic
mechanism regulated by 15d-PGJ2, but not by ciglitazone,
was related to the production of ROS and the reduction
in intracellular GSH [94]. CD40 signaling through CD40-
ligand (CD40L) enhances B cell survival and prevents BCR-
induced apoptosis by activating the transcription factor
NF-κB[ 188]. Therefore, we tested whether CD40 ligation
could protect normal and malignant B cells from PPARγ
ligand-inducedapoptosis.CD40Lwasabletopartiallyrescue
normal and malignant B cells from PPARγ ligand-induced
apoptosis by activating NF-κB. Similarly, Piva et al. reported
15d-PGJ2-induced apoptosis in human Burkitt’s lymphomas
andmultiplemyelomacelllinesthroughinhibitionofNF-κB
activity. These eﬀects lead to the downregulation of NF-κB-
dependent antiapoptotic protein production and therefore
decreased cell survival. The apoptotic eﬀects could also be
mimicked by NF-κB p65 subunit knockdown by siRNA
[189]. These results suggest a possible mechanism for the
proapoptotic action of PPARγ agonists.
We have also demonstrated that PPARγ ligands can
induce apoptosis in cells from human T cell leukemias
(Jurkat), lymphomas (J-Jahn), and T-ALL cells (CCRF-
CEM) by a PPARγ-dependent mechanism [103]. Interest-
ingly, normal T cells were not adversely aﬀected by PPARγ
ligands, suggesting the use of PPARγ agonists as selective
therapeutic drugs for T-cell malignancies [103]. However,
data from Yang et al. raised questions on the antiproliferative
eﬀects of PPARγ-ligands in T-lymphoma cells [190]. They
demonstrated that low concentrations of PPARγ-ligands
promoted T-lymphoma cell survival, while high concen-
trations promoted cell death. These results suggest that in
T-lymphoma cells, PPARγ ligands can have contradictory
eﬀects when used at diﬀerent concentrations and require
further examination.
Cutaneous T cell lymphoma (CTCL) is a group of T cell
malignanciesthataccumulateintheskin.Themostcommon
CTCLs are (1) the Mycosis fungoides (MF), which develops
as patches, plaques, or tumors containing apoptosis-resistant
CD4+ CD45RO+ helper/memory T cells; and (2) the S´ ezary
syndrome (SS), which is the leukemic form of CTCL that
develops with erythroderma and the appearance of atypical
T cells in the peripheral blood [191]. Current therapies
for CTCL include the use of bexarotene, an RXR ligand,
with good eﬃcacy in the late stages of the disease [191].
Zhang et al. demonstrated the expression of PPARγ in
three CTCL lines (MJ, Hut78, and HH) and freshly isolated
peripheral blood lymphocytes (PBL) from SS patients with
circulating atypical T cells (CD4+CD26−)[ 192]. CDDO
exposure caused a dose-dependent induction of apoptosis
in MF/SS cell lines and SS patients’ PBL [192]. These
ﬁndings suggest that PPARγ ligands may be beneﬁcial for
thetreatmentofCTCLandmayhavesynergisticeﬀectswhen
used in combination with bexarotene.
Mantle cell lymphoma (MCL) is a rare type of non-
Hodgkin’s lymphoma (NHL), constituting about 6% of
NHL [193, 194]. In 85% of MCL cases, a translocation
between chromosome 11 and 14, t(11;14), is involved in the
pathogenesis. This translocation leads to the overexpression
of cyclin D1, a protein that increases cell survival and
proliferation by positively regulating cell cycle entry into
the S-phase [193]. Despite the success of current therapies,
patients with mantle cell lymphoma have a shorter life
span compared to patients with other B cell lymphomas
[193]. Recently, a study demonstrated that treatment with
pioglitazone and rosiglitazone, as well as with 15d-PGJ2
induced MCL cell apoptosis and downregulated cyclin D1
expression without altering cell cycle progression [195].
5.2.2. Chroniclymphoblasticleukemia(CLL)and
diffuselargeBcelllymphoma(DLBCL)
CLL is a clinically heterogeneous disease originating from
B lymphocytes that diﬀer in activation, maturation state,
or cellular subtype [196]. CLL is one of the most common
forms of leukemia in adults [141]. In B-CLL, resistance
to apoptosis has been associated with increased Bcl-2
expression, due to either promoter hypomethylation or to
chromosomaldeletionofthegeneswhichencodetwonatural
Bcl-2 antisense RNAs [197, 198].
To date, there are few studies that evaluate the use of
PPARγ-ligands against these malignancies. The eﬀects of the
triterpenoidCDDOwereevaluatedinrefractoryB-CLLcells.
CDDO induced apoptosis in a dose-dependent manner in
both previously untreated and chemoresistant CLL samples
[199]. In this study, CDDO induced the activation of
caspase-8, but not caspase-9, indicating the involvement of
a mitochondrial-independent pathway [199]. CDDO also
negatively aﬀected the levels of an endogenous caspase-8
inhibitor,c-FLIP(caspase-8homologFas-ligandinterleukin-
1-converting enzyme (FLICE)-inhibitory protein). However,
downregulation of c-FLIP expression was not the sole path-
wayactivatedbyCDDO,asc-FLIPantisenseoligonucleotides
did not induce CLL apoptosis [199]. Subsequently, Inoue
et al. further investigated the mechanism of CDDO-induced
apoptosis in primary B-CLL and Jurkat cell lines. In contrast
to the studies discussed earlier [160, 164, 199], where CDDO
activatedboththeintrinsicandextrinsicapoptoticpathways,
Inoue et al. proposed that CDDO induces apoptosis exclu-
sively through the intrinsic pathway [200]. In their study,
CDDO exposure induced an initial caspase-independent
mitochondrial depolarization, followed by caspase cleavage.
Using caspase inhibitors, the authors were able to deﬁne
caspase 9 as the primary activated caspase. Moreover, CDDO
induced cell death in caspase-8 and FADD-deﬁcient but
not in Bcl-xL-overexpressing Jurkat T cells. In CLL, CDDO
induced an initial release of proapoptotic intermediates,
cytochrome c, and Smac/DIABLO from the mitochondria
andledtoapoptosis[200].Accordingtotheseresults,CDDOTatiana M. Garcia-Bates et al. 9
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Figure 3: Mechanisms of action of PPARγ ligands in hematological malignancies. PPARγ ligands can bind to and activate PPARγ to
regulate gene transcription or they can exert PPARγ-independent mechanisms. PPARγ ligands have antiproliferative, prodiﬀerentiation,
antimetastatic, and proapoptotic eﬀects on several hematological malignancies making them promising candidates for use in therapeutic
regimens.
mainly activates the intrinsic apoptotic pathway in both cell
lines [200].
Diﬀuse large B-cell lymphomas (DLBCLs) are the most
common lymphoid neoplasms, composing 30–40% of adult
NHL [201]. The gene expression pattern (using DNA
microarrays) of DLBCL was compared with that of normal
B cells, including those from the germinal center (GC) and
in vitro-activated peripheral blood B cells [202]. Based on
the results, DLBCL were classiﬁed into two groups: those
resembling B cells from the GC (GC-DLBCL) and those
resembling in vitro-activated B cells (ABC-DLBCL). Patients
with cancer of the GC-DLBCL-type have a more favorable
prognosis than those with the ABC-DLBCL-type [202].
Although some DLBCL patients are cured with current
therapies, most succumb to the disease. In addition, poor
prognosis correlates with Bcl-2 overexpression, which may
be responsible for the impaired apoptotic response of ABC-
DLBCL to chemotherapy [203, 204].
Recently, a study by Ray et al. showed that CDDO
induced growth inhibition and apoptosis in human DLBCL
and that these eﬀects were PPARγ-independent [205]. Inter-
estingly, CDDO induced NF-κB activation and enhanced
DLBCL apoptosis when combined with NF-κB inhibitors.
These ﬁndings suggest that NF-κBm a yb ea c t i v a t e da s
a survival pathway to antagonize the apoptotic eﬀects of
CDDO [205] .Ar e c e n ts t u d yb yB r o o k e se ta l .e l u c i d a t e d
another mechanism for CDDO-induced cell death [206]. In
this study, CDDO, CDDO-Im, and the dinitril derivative of
CDDO, Di-CDDO induced both normal and malignant B
cell apoptosis. The CDDO derivatives were more eﬀective
than CDDO itself. It was demonstrated that CDDO directly
interacted with and modiﬁed several mitochondrial protein
thiols, resulting in large molecular weight protein aggregates.
These aggregates led to a loss in mitochondrial thiol
status by constitutively opening cyclosporin A-insensitive
permeability transition (PT) pores [206], thereby reducing
mitochondrial transmembrane potential and resulting in
cell death. These ﬁndings suggest a novel mechanism for
triterpenoid-induced cell death and predict the development
of new therapeutic drugs that can elicit unregulated PT pore
formation in cancer cells.
5.3. Multiplemyeloma
Multiple myeloma (MM) is a neoplastic disorder char-
acterized by clonal proliferation of diﬀerentiated plasma
cells in the bone marrow, accompanied by accumulation
of monoclonal paraprotein levels in serum and urine.
Common clinical symptoms include bone lesions, anemia,
immunodeﬁciency, and renal failure [207]. MM constitutes
∼10% of hematological cancers and ranks as the second
most frequent hematological malignancy in the United
States after NHL [208, 209]. Current therapies for the
disease include chemotherapy with or without stem cell10 PPAR Research
transplantation, glucocorticosteroids, thalidomide, and the
proteasome inhibitor Bortezomib (Velcade) and combina-
tions of these agents. However, most of these treatments
are not curative, and newer approaches are needed [209].
The therapeutic potential of PPARγ ligands has also been
e v a l u a t e di nM M[ 13, 210, 211]. PPARγ agonists have been
demonstrated to have inhibitory eﬀects in Waldenstrom’s
macroglobulinemia (WM), a rare plasma cell malignancy
[212]. In addition, our laboratory demonstrated that human
multiple myeloma cells modestly express PPARγ.T r e a t -
ment with PPARγ ligands induced MM apoptosis via
caspase activation and mitochondrial depolarization. These
proapoptotic eﬀects were not reversed by the addition of
the MM growth factor IL-6. Moreover, we showed that
these cells express RXR and that addition of an RXR lig-
and (9-cis-RA) enhanced PPARγ-ligand-induced apoptosis
[210]. Farrar’s group found that PPARγ ligands 15d-PGJ2
and troglitazone completely abolished IL-6-dependent MM
cell proliferation and induced apoptosis. PPARγ agonists
inhibited MM cell survival by speciﬁcally blocking the IL-6-
dependent transactivation of STAT3 (signal transducer and
activator of transcription)-activated genes, including c-myc
and mcl-1 [13]. Recently, the same group has revealed that
PPARγ ligands inhibit (1) MM cell adhesion to bone marrow
stromal cells (BMSC), (2) MM cell expression levels of
adhesion molecules, and (3) BMSC secretion of IL-6, which
is triggered by MM cell adhesion. The inhibitory eﬀects of
PPARγ ligands correlated with PPARγ-dependent transre-
pression of the transcription factors 5 -CCAAT/enhancer-
binding protein β (C/EBP-β)a n dN F - κB[ 213]. The PPARγ
ligands CDDO and CDDO-Im have also been tested in MM
cells, both alone and in combination with the proteasome
inhibitor PS-341 (Bortezomib) [214–216]. The mechanisms
of CDDO-induced apoptosis include loss of mitochondrial
membrane potential, which increases release of ROS and
depletes glutathione, as well as activation of caspases and
reduction of c-FLIP protein levels [214]. These results
correlated with the studies described earlier, using CDDO
in CLL [199]. Combination treatments of CDDO-Im with
Bortezomib had synergistic apoptotic eﬀects in MM cells
[215], abolished NF-κB and Bcl-2-mediated cytoprotective
eﬀects and overcame drug resistance to Bortezomib [215].
Overall, these ﬁndings suggest the use of CDDO-Im, either
alone or in combination with bortezomib, to treat drug-
resistant MM and improve patient prognosis.
6. CONCLUSIONSAND FUTURE DIRECTIONS
In summary, although the exact role of PPARγ in controlling
malignantcellgrowthandapoptosisremainsunclear,PPARγ
has been commonly implicated as a tumor suppressor in
hematological cancers (see Figure 3 for overview). Evidently,
a better understanding of the mechanism of action of PPARγ
is needed. It is important that studies be performed to
carefully analyze PPARγ levels, as well as the activation
status of PPARγ in hematological cancers. In addition, since
many of the existing studies have demonstrated that the
proapoptotic and antiproliferative eﬀects of PPARγ ligands
are independent of the receptor; additional studies are
required to elucidate PPARγ-dependent from independent
events by using tissue speciﬁc knockouts, siRNA approaches,
and overexpression studies. Understanding the mechanisms
of action of these agents has become a priority to develop
drugs that have beneﬁcial eﬀects on tumor suppression
without having major side eﬀects. Certain advances may
be possible through the discovery of SPPARγMs that can
activate only a subset of desired genes. This will require
the identiﬁcation of PPARγ target genes that mediate the
antitumorigenic eﬀects in hematological malignancies.
ThefactthatPPARγ canbemodiﬁedbyphosphorylation
through MAP kinases and that this modiﬁcation decreases
PPARγ transcriptional activity, and the fact that PPARγ acti-
vation itself increases PPARγ degradation by the proteasome
may be exploited for therapeutic beneﬁt. PPARγ ligands
in combination with inhibitors of MAP kinases and/or
proteasome inhibitors (e.g., Bortezomib) may be useful in
the treatment of malignancy. Therefore, studies should be
performed to assess the eﬀectiveness of these combination
therapies as well as those combining PPARγ ligands with
drugs such as Imatinib or RXR/RAR ligands. Our current
knowledge of the anticancer potential of PPARγ ligands
predicts that such therapies may prove to be of great beneﬁt
for future treatments of hematological cancers.
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